CClinicalTrials.gg
Status unknownNCT00624572Updated Feb 27, 2008

Efficacy of Chlorexidine as Intracanal Medicament in Primary Teeth

A Phase 2 interventional study of chlorexidine in Dental Pulp Necrosis, sponsored by Universidade Federal do Ceara. Status unknown at 1 site in Brazil. Open to participants aged 4 Years to 8 Years. Per ClinicalTrials.gov, last updated 2008-02-27.

Sponsored by Universidade Federal do Ceara · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2008), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
4 Years to 8 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the action of the chlorexidine as intracanal medicament in the reduction of the levels of bacteria inside root canals of primary molar teeth with pulpal necrosis.

02

Conditions studied

  • Dental Pulp Necrosis

Keywords

  • primary teeth
  • chlorexidine
  • root canal therapy
  • Pulpectomy
03

In context

Dental Pulp Necrosis

149 studies on the registry are indexed under Dental Pulp Necrosis; 39 are open to participants now.

This study's planned enrollment of 30 is below the median of 44 across 139 interventional studies indexed under Dental Pulp Necrosis.

Browse Dental Pulp Necrosis studies →

Lead sponsor

Universidade Federal do Ceara is the lead sponsor of 21 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Healthy children of both gender;
  • Without history of reactions or alergical diseases;
  • With situated age between 04 and 08 years of age
  • With normal standard of growth and development
  • Patients with necessity of radical endodontic treatment (pulpectomy) in, at least, two primary molar teeth in different hemi-arches.

Exclusion criteria

Exclusion Criteria:

  • Patients with history of alergical diseases
  • Patients with allergy to any type of medicine and/or foods
  • Patients with comprometimento of its general state of health
  • Healthy patients with risk to develop bacterial endocardite or patients that their general state of health can be aggravated had the transitory bacteremies, as for example children with congenital cardiac illnesses
  • Patients who are making use of sistemis antibiotics, or that they have made use of sistemic antibiotic in the period of 3 (three) months before the beginning of the endodontic treatment
  • With periapical x-ray evidencing less than 2/3 of remaining root of the primary tooth to be treated
  • Patients whose tooth with endodontic necessity to meet in advanced state of root pathological reabsortion
  • Patients whose legal responsible or parents to refuse to sign the term of free and clarified assent
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Interventions

  • Drugchlorexidine

    Chlorexidine gel 1% during 7 days inside root canals

06

Study locations

1 site
  • Ramille Araújo Lima
    Fortaleza, Ceará 60440-810, Brazil
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 27, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00624572
Lead sponsor
Universidade Federal do Ceara
First posted
Feb 27, 2008
Start date
Oct 2007
Primary completion
Nov 2008 (estimated)
Completion
Feb 2009 (estimated)
Last update
Feb 27, 2008
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion